[{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-100)","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Eton Pharmaceuticals"},{"orgOrder":0,"company":"Enzychem Lifesciences Corporation","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Enzychem Lifesciences Selected to Collaborate with NIAID CCRP on the CERF Program","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Undisclosed","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Enzychem Lifesciences Corporation"},{"orgOrder":0,"company":"CMC Pharmaceuticals","sponsor":"U.S. Defense Department","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CMC Pharmaceuticals Awarded SBIR Grant for Concentrated Atropine Formulation","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"CMC Pharmaceuticals"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The Phase I SBIR award will fund the formulation and analytical development of a concentrated Atropine Sulfate Drug Product with the aim to aid the military in treating organophosphate poisoning in service members.
Enzychem's lead compound, EC-18, is an immunomodulator that rapidly resolves inflammation and restores immune homeostasis by accelerating the intracellular trafficking of pattern recognition receptor-bound pathogenic invaders or endogenous danger signals.
Eton Pharmaceuticals has submitted a new drug application (NDA) for dehydrated alcohol injection, previously known as the company’s DS-100 product candidate, to the U.S. Food & Drug Administration (FDA) for the treatment of methanol poisoning.